News
SOURCE: Biopharm International
Synthetic DNA as an Alternative to Plasmids
Synthesis of DNA via cell-free methods has many benefits versus fermentation. Advanced technologies, with higher-throughput and smaller footprints that replace fickle cells with more repeatable in vitro approaches, are likely the answer to the growing need to iterate fast in R&D and transition to clinical in a fraction of the time it takes today.
SOURCE: R&D World
4 DNA and Genomics Advances Recognized in R&D 100 Awards in 2024
DNA technologies were one of the focus areas of this year’s R&D 100 Awards, with winners showcasing advances in forensic analysis, synthetic DNA production, and sequencing accuracy. This article recaps four DNA and genomics advances recognized in the 2024 awards, among them Elegen’s ENFINIA DNA technology, which can achieve 20x higher accuracy in synthetic DNA production.
SOURCE: The Healthcare Technology Report
The Top 100 Healthcare Technology Companies of 2024
The Healthcare Technology Report is pleased to announce its annual awards for The Top 100 Healthcare Technology Companies. This year’s awardees were selected based on a methodical review of nomination submissions as well as further in-depth research into each candidate’s products and solutions, corporate track record, management team caliber, and organizational depth, among other factors.
SOURCE: Biotech Breakthrough Awards
2024 BioTech Breakthrough Awards Program Celebrates Groundbreaking Biotechnology Innovators Around the World
Elegen’s ENFINIA™ DNA has been named “DNA Synthesis Technology Of The Year” by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.
SOURCE: Analytical Chemistry
Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses
Messenger RNA vaccines have shown their value for a broad range of therapeutic applications, ranging from cancer immunotherapy to infectious diseases. Additionally, vigorous efforts are now being devoted to the use of IVT mRNA technology for other uses such as cell therapy and gene editing. While these mRNA-based approaches show great promise as next-generation therapeutics, there are still many open questions about the effect of mRNA impurities that can occur during the IVT reactions.
SOURCE: Biocompare
Accelerating the Pace of Drug R&D with Synthetic Biology
Biocompare recently spoke with several companies, including Elegen, that have developed critical enabling technologies for drug discovery and development with synthetic biology, gaining valuable insight into its current achievements, what the future looks like, and key areas that need to be addressed for us to get there
SOURCE: R&D World
R&D 100 Winners for 2024 Are Announced
The official 2024 R&D 100 Awards have been announced by R&D World, and Elegen’s ENFINIA DNA is a winner!
SOURCE: R&D World
R&D 100 Finalists for 2024 Are Announced
A total of 141 Finalists for the 2024 R&D 100 Awards have been announced by R&D World. This renowned worldwide science and innovation competition, celebrating its 62nd year, received entries from 16 different countries and regions. Elegen’s ENFINIA DNA, next-generation gene synthesis manufactured entirely cell free, is among the finalists.
SOURCE: bioRxiv
Active Learning-Assisted Directed Evolution
Researchers from the California Institute of Technology describe a new method that alternates between library synthesis/screening and machine learning (#ML) to optimize mutations and unlock a more efficient, effective, and faster DBTL cycle for protein engineering. Elegen’s ENFINIA DNA delivered sequence-perfect genes within a week to accelerate optimization cycles.
SOURCE: Genetic Engineering News
eBook: Advancing mRNA Vaccine and Therapy Development
This Genetic Engineering News eBook reviews advances in mRNA vaccine and therapy development, including next-generation gene synthesis via cell-free cloning.
SOURCE: Genetic Engineering News
Enzymatic DNA Synthesis: Shorter Waits, Longer Strands
Genetic Engineering News reviews several DNA manufacturing technologies that have emerged to give synthetic biology companies what they need to revolutionize the life sciences.
SOURCE: BizTech Outlook
Elegen Named Among Top 10 Innovative Companies of 2024
BizTech Outlook named Elegen among the Top Innovative Companies to Watch in 2024. Read this interview to learn why innovation is this company’s DNA.
SOURCE: Elegen News
Elegen Raises $35 Million in Series B to Accelerate Expansion into Clinical Manufacturing
Elegen announced a Series B financing of $35 million led by Triatomic Capital. Also joining the round are strategic investors GSK, which recently entered a collaboration and licensing agreement with Elegen to use their proprietary cell-free DNA manufacturing technology in developing GSK’s vaccines and medicines; John Ballantyne, co-founder of Aldevron; and existing investors.
SOURCE: Big4Bio
Elegen’s High-Complexity DNA Synthesis Accelerates the Development of Designer Polyketide Molecules
The Keatinge-Clay lab at the University of Texas at Austin ordered de novo synthesis of a 14,713 bp plasmid containing a PKS gene cluster. Elegen’s rapid, full-length plasmid synthesis saved the lab weeks of assembly time and labor when compared to traditional approaches. With Elegen’s ability to synthesize regions of high complexity, labs are able to move projects with difficult, complex sequences, including repetitive GC-rich regions, from the drawing board to the incubators in a matter of weeks.
SOURCE: Big4Bio
Big4Bio Podcast: Solving Major Bottlenecks in Genetic Medicine and SynBio with DNA Synthesis Innovation
In this episode of Big4Bio’s Company to Watch, Danny Levine interviews Matthew Hill, Ph.D., founder and CEO of Elegen, on the next big innovation in manufacturing DNA, which bypasses synthetic DNA bottlenecks to accelerate upstream and downstream workflows.
SOURCE: Big4Bio
Removing Bottlenecks in Synthetic Biology with Cell-Free Synthesis of Long and Complex DNA
Randy Dyer, Vice President of Marketing, discusses the mission to unlock the promise of synthetic biology by eliminating a critical bottleneck in the supply of synthetic DNA for genetic medicine development and other biotechnology applications.
SOURCE: Elegen News
Elegen Launches ENFINIA™ DNA Enhancement for Rapid Synthesis of Highly Complex DNA
Following successful, fully subscribed Early Access and Beta Programs, Elegen’s latest ENFINIA DNA enhancement provides access to very challenging sequences, including long repeats and STRs, GC-rich promoters, enhancers, terminators, ITRs, LTRs and homopolymers.
SOURCE: Fast Company
The World's Most Innovative Companies of 2024
Elegen has been named among the world’s most innovative companies by Fast Co., ranked #2 in “Small but Mighty.”
SOURCE: The Healthcare Technology Report
The Top 25 Biotechnology Companies of 2024
Elegen has been named among the Top 25 Biotechnology Companies of 2024 by the Healthcare Technology Report.
SOURCE: BioCompare
Improving Cell and Gene Therapy Process Development
Cell and gene therapies (CGT) represent the cutting edge of biotherapeutics, using DNA and life itself as therapeutic agents. CGT process development requires the coordination of many parts, including cells, DNA constructs, and gene delivery vectors. As a key starting material, CGT development requires a constant flow of high-accuracy, long, and complex custom DNA. Elegen is addressing this synthesis bottleneck with its cell-free DNA synthesis process.
SOURCE: SynBioBeta
Health and Medicine News: Elegen Partners with GSK
Exclusive Interview: Elegen CEO Matthew Hill on new collaboration with GSK.
SOURCE: Life Science Success Podcast
Life Science Success Podcast: Cell-free DNA Synthesis of Industry Leading Long and Complex DNA
In this episode of Life Science Success Don Davis interviews guest Matt Hill, founder and CEO of Elegen, a privately-held company based in the San Francisco Bay Area, committed to revolutionizing synthetic biology workflows with an innovative DNA writing technology.
SOURCE: Genetic Engineering News
GSK and Elegen Team Up to Develop DNA-Based Medicines and Vaccines
Elegen’s ability to produce NGS-verified linear DNA up to 7 kb within a week with error rates as low as 1:70,000 per bp (99.999% per base accuracy) could be an important marker as it tries to establish a leading position in a heated race to deliver what could be the next major medicinal breakthrough.
SOURCE: Elegen News
Elegen Announces Multi-Year Collaboration and Licensing Agreement with GSK
GSK has signed a collaboration & licensing agreement to leverage Elegen’s cell-free DNA manufacturing technology in the development of GSK’s vaccines & medicines.
SOURCE: Business Intelligence Group
11 Executives, 47 Companies and 108 Products Win 2024 BIG Innovation Award
Business Intelligence Group Announces the Winners of the 2024 BIG Innovation Awards
SOURCE: Technology Networks
Synthetic DNA Advances Will Catalyze the Next Wave of Biotherapeutic Innovation
Recent innovations in DNA manufacturing are helping eliminate critical bottlenecks to bring new therapies to market faster than ever.
SOURCE: Nature Biotechnology
DNA Writing Technologies Moving Towards Synthetic Genomes
Nature reviews the latest advancements in DNA synthesis and the key challenges the new players like Elegen are quickly overcoming.
SOURCE: Biocompare
Cell Expansion for Cell Therapies
Biocompare recently published on the challenges of scaling cell therapies. Part of this challenge starts UPSTREAM in determining the optimal DNA sequence for expansion–a time-consuming, resource-intensive process.
SOURCE: Drug Discovery World Magazine
Accelerating Biotherapy and Personalized Medicine with Long DNA
Matt Hill, Founder and CEO of Elegen writes about the importance of innovation in DNA synthesis to address critical bottlenecks in biotherapy development.
SOURCE: BIOS Community
BIOS Builders Episode 15
Podcast featuring Matt Hill – Founder & CEO of Elegen
SOURCE: Elegen News
Elegen Early Access Partners Receive High-Complexity, Long DNA Sequences in Rapid Time
DNA lengths of 15,000 base pairs and higher represent twice the length of the Company’s recently launched flagship product, ENFINIA DNA, and industry-leading complexity and turnaround time
SOURCE: Elegen News
Elegen Launches New Online Ordering Portal for Rapid, High-Accuracy, Long DNA
Company focuses on ease of use, utility, and speed to increase ENFINIA DNA’s impact on workflow efficiency and productivity.
SOURCE: Forbes
Synthetic Biology Is Set to Explode, but Only Once This Huge Bottleneck Is Gone
Guest author John Cumbers, CEO of SynBioBeta meets with Elegen Founder and CEO, Matthew Hill
SOURCE: Mendelspod
Elegen Pioneers Long DNA Subindustry with CEO, Matt Hill
Mendelspod Podcast Featuring Elegen CEO and Founder, Matthew Hill
SOURCE: GenomeWeb
Synthetic DNA Startup Elegen Gains Traction with Customers, Funders
Note: GenomeWeb Premium Subscription Required
SOURCE: Elegen News
Elegen Launches ENFINIA™ DNA
New product delivers up to 7kb of high-accuracy DNA in as fast as 7 days, providing an unparalleled combination of speed, length, and quality to the synthetic biology market
SOURCE: Genetic Engineering News
Enabling the Synthetic Biology Revolution
The team at Elegen knows that when barriers to the fast, accurate, and low-cost synthesis of long DNA fall, biotechnology will be driven by the design-build-test-learn cycle